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Following publication of the Dutch-Belgian NELSON 
trial, which confirmed the findings of the US National 
Lung Screening Trial (NLST) published a decade earlier, 
that low radiation dose CT (LDCT) screening reduces 
lung cancer mortality, many countries are planning to 
introduce screening programmes for lung cancer targeted 
to people at high risk of the disease. The success of such 
programmes depends on a number of factors that have 
been extensively researched and several resultant position 
statements are available to guide those implementing 
programmes (1-3). However, some issues remain a pressing 
concern because there is no clear consensus on how they 
should be addressed. Informed uptake, participation, and 
adherence (to successive screening rounds) are related 
issues that impact on the equity and cost-effectiveness of 
a programme as well as the overall impact on lung cancer 
mortality. It is also important to recognise that choosing 
not to participate in lung cancer screening is a legitimate 
choice, although evidence suggests that a decision not to 
participate is often uninformed (4). In this article we discuss 
the participation rates observed in some clinical trials 
and in pilot programmes and review the factors that may 
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influence uptake, drawing on evidence from other screening 
programmes and interventions in similar target populations.
Participation rates and inequalities in lung 
cancer screening
Participation in screening programmes for cervical, breast 
and colorectal cancer is around 75%, 70% and 60% 
respectively in the UK (5-9). This is the rate of uptake of 
the offer and attendance at the screening test (for breast 
and cervical cancer) or return of the test (colorectal cancer). 
In lung cancer screening, it is the proportion of people 
that attend the assessment appointment. The proportion 
who actually undergo the LDCT is often also quoted. The 
rationale for this is that there is a further check on eligibility 
in the screening assessment process which is not a measure 
of participation. Uptake is lower in socioeconomically 
deprived groups (10) and among current smokers (11), 
where the highest rates of lung cancer are seen. This is 
important because currently, LDCT is only offered to 
those at high risk of lung cancer for whom the risk-benefit 
ratio is favourable. The evidence from clinical trials in lung 
cancer screening is limited because only one has used a true 
population approach in recruitment, the United Kingdom 
Lung Screen pilot trial (UKLS) (12), and offering screening 
as part of a clinical trial may underestimate the participation 
rates of a real-world service (13). In the UKLS trial, 31% 
of eligible people responded to an initial questionnaire 
but only 11.5% of participants were at high enough risk 
for trial entry and 47% of these gave their consent. In 
the NELSON trial a population approach was initially 
used for adult males only. Thirty-two percent of those 
eligible responded to a questionnaire on general health, 
lifestyle, and smoking history (which did not mention the 
NELSON trial) (14). Nineteen percent of the respondents 
met the eligibility criteria for the trial and received an 
invitation for participation in the trial, an information 
leaflet, and an informed consent form combined with 
a short questionnaire (14). Of these individuals, 51% 
gave informed consent and were recruited. The lower 
participation rate in the UKLS may in part be explained 
by the eligibility criteria that required a higher risk of lung 
cancer than in NELSON. 
However, in both well-conducted trials, current smokers 
at higher risk were less likely to participate than former 
smokers (15-17). A more detailed analysis showed that 
female sex, older age, and more deprived socioeconomic 
background were independent determinants of reduced 
participation in UKLS (18). Similarly in NELSON, which 
recruited mostly men (84%), participants were younger 
and had a higher level of education than eligible non-
responders, and also reported better health and increased 
physical activity (19). Indeed, these same demographic and 
smoking-related inequalities in participation have been 
observed internationally across several other lung screening 
trials, including the NLST (20) and the Danish Lung 
Cancer Screening Trial (21). 
The participation rate of people at higher risk was low 
enough to be of concern for the successful implementation 
of lung cancer screening programmes. Where a more 
conventional approach to recruitment has been employed, 
participation rates have so far been low. In the US, where 
LDCT screening has been funded since 2015 (22), 
participation rates were 3.3% of the eligible population 
in 2015 and more recently estimated to be 14% in 2018 
although only 4% in the uninsured (23,24). That this effect 
was observed among socioeconomically deprived groups 
(25) is not unexpected; echoing previous work in smoking 
cessation (26,27) as well as a pervasive social gradient in 
uptake of established population screening programmes 
for other cancer types (10). Research into high-risk groups’ 
attitudes to lung cancer screening has identified potential 
psychological barriers to taking part; most frequently 
reported by individuals of a socioeconomically deprived 
background. These included a nihilistic view of lung cancer 
which was perceived as an uncontrollable disease with 
attitudes of fatalism, self-blame, low perceived treatment 
efficacy and stigma (28,29). 
However, it is critical that future programmes engage 
high-risk groups equitably, to ensure this population 
benefits and to avoid exacerbating existing inequalities in 
lung cancer mortality. The health gains from screening 
the more deprived group are not well-defined; in both 
NLST and NELSON, participants were better educated, 
younger, and less likely to be current smokers compared 
to background population smoking rates (30) or non-
responders (17) respectively. Whilst individuals from 
socioeconomically deprived backgrounds may have higher 
frequencies of competing causes of death, they are also 
more likely to be current smokers, so the potential health 
gain from LDCT screening and smoking cessation may be 
greater. Participation rates amongst women are lower than 
men in most trials and pilots (12,30), yet the reduction in 
mortality is greater in women (31,32). Further work may 
be needed that focuses on factors which improve uptake in 
women.
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In an effort to enhance informed participation in lung 
cancer screening, there has been a recent focus on pilot 
programmes targeted within socioeconomically deprived 
areas of the UK. Pilot screening programmes in Liverpool, 
Manchester, Leeds, Nottingham, and London have 
concentrated recruitment efforts in deprived areas (32-
36). Only the London-based Lung Screen Uptake Trial 
(LSUT) has reliably measured participation rate amongst 
people identified through primary care records and used 
a randomised controlled real world demonstration design 
to ascertain uptake in the service context (36). This 
demonstration pilot showed a participation rate of 53%, 
of which 91% of those eligible chose to be screened, 
comparing favourably with uptake of bowel cancer 
screening in similar populations (37). In the other pilots 
participation rate was difficult to measure, but whether fixed 
site (Liverpool) or mobile (Manchester and Nottingham) 
scanners were used, 35–53% of eligible attendees 
subsequently participated in LDCT screening across all 
pilots. All of these pilots identified ever smokers potentially 
at risk of lung cancer and the first contact was from the 
primary care doctor. 
Improving participation in cancer screening
While evidence for strategies that improve participation 
in lung cancer screening is relatively limited, useful 
insight may be drawn from previous research in other 
screening programmes or other healthcare interventions 
in similar populations. Interventions that are consistently 
associated with improved participation include the use 
of pre-invitation letters, scheduled appointments, and 
reminder letters (38-40). In particular, the use of social 
media messaging and text reminders in prompting cancer 
screening engagement remains an area of active research.
Primary care endorsement has been shown to have 
a modest effect on uptake of colorectal screening of 
6–7% (41,42), although this did not appear to change the 
socioeconomic gradient. In colorectal screening, uptake 
in the Scottish and Australian programmes was increased 
by 24 and 23% respectively through the use of pre-
notification letters (38,43). In the Scottish programme, 
this was true for all socioeconomic groups. Provision of 
enhanced procedural information prior to colorectal cancer 
screening was associated with improved uptake rates of 
between 0 and 6% (41,42). Reminder letters were found 
to increase colorectal screening uptake by 7% overall and 
by 11% in deprived groups, indicating some impact on 
the socioeconomic gradient (42). Breast cancer screening 
uptake was increased by 19% by reminder letters sent a 
few days prior to appointment for a mammogram (44). 
Indeed, Duffy and colleagues’ rapid review of interventions 
designed to improve cancer screening participation found 
reminders (postal, text and telephone) were consistently 
associated with higher uptake; with letters achieving the 
largest increase (relative to telephone) and personalised 
letters for non-participants being particularly effective (39). 
Pre-scheduled appointments have been shown to increase 
rates of attendance 3-fold in breast cancer screening (45) 
and timed second appointments for non-attenders resulted 
in 20% attending for screening, contributing a 6% overall 
increase in screening uptake (46). In LSUT, a reminder 
letter providing a second pre-scheduled appointment 
increased uptake of lung cancer screening among non-
responders by 24% (36). In addition, recorded delivery 
letters and incentives, including financial, are associated 
with improved participation (47). 
Understanding and improving participation in 
lung cancer screening
Optimising informed participation rates in lung cancer 
screening remains a  key priority for successful ly 
implementing effective and equitable programmes. 
According to the ‘COM-B (Capability, Opportunity, 
Motivation – Behaviour) system’ framework, which is the 
central component of Michie and colleagues’ ‘Behaviour 
Change Wheel’ (Figure 1) (48), there are three necessary 
conditions for any given behaviour: capability (the 
individual’s psychological and physical capacity to engage 
in a behaviour), opportunity (the physical and social 
resources needed to enact a behaviour) and motivation (the 
individual’s cognitive and affective processes that direct 
behaviour). These conditions are proposed to interact to 
determine whether a behaviour is enacted. For example, 
if opportunity were high and motivation were low, an 
individual may still engage in a behaviour because it was 
made easy to do so. On the other hand, if opportunity 
were low and motivation were high, an individual may 
persist with a difficult behaviour because they felt strongly 
motivated. In both scenarios, these individuals’ behaviour 
may be thwarted if their capability (actual or perceived) 
were low. 
With regards to opportunity and capability, almost half 
of non-participants surveyed (n=748) in UKLS identified 
practical barriers relating to travel and comorbidities (18). 
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Comorbidities are relatively more common among the 
screening-eligible population compared with the general 
population due to the adverse health effects of long-term 
smoking and social deprivation being associated with 
increased rates of disability. Qualitative research in the US 
with those opting out of lung cancer screening also reported 
practical concerns; including the inconvenience of the 
screening location and the time taken to travel and have the 
scan alongside full-time employment (49). In another US 
study, the potential cost of screening was a further practical 
concern, particularly among participants of an ethnic 
minority background (50).
Research into high-risk groups’ attitudes to lung cancer 
screening has also identified potential psychological factors 
that may undermine an individual’s motivation to take 
part. These included a nihilistic view of lung cancer which 
was perceived as an uncontrollable disease with attitudes 
of fatalism, self-blame, low perceived treatment efficacy, 
stigma, and in the US, distrust of the healthcare system 
(28,29,51). A fifth of those declining participation in UKLS 
reported emotional barriers reflecting concern about their 
risk of lung cancer (affective risk perception), and fear and 
avoidance of lung cancer information; most frequently 
among current smokers (18). Population-based surveys 
within the UK have shown avoidant beliefs about lung 
cancer screening and an intention not to be screened were 
associated with fatalism, low perceived treatment efficacy 
and survival benefit, and not being willing to have surgery 
for a screen-detected early stage lung cancer (52,53). 
Ways in which to further increase participation, using 
these insights as well as evidence-based strategies from 
screening programmes for other cancer types, were tested 
in the LSUT. The intervention invitation materials were 
designed to be ‘targeted, stepped and low burden’; with 
targeted content aiming to minimise fear, fatalism and 
stigma and to provide a low burden level of information prior 
to the appointment (54). There was no overall difference 
in participation rate between the intervention materials 
and control invitations. However, uptake was improved 
among those with the highest levels of deprivation 
which importantly provides evidence for a reduced social 
gradient, and participation rates in both arms of the 
trial were significantly higher than has previously been 
observed (36). This may reflect the application of the 
measures supported by existing evidence in both arms of 
the trial, designed to improve opportunity and capability 
to reduce non-intentional barriers to participation across 
both arms. These included primary care invitations, pre-
notification letters, scheduled appointments, and reminders 
(with a second scheduled appointment). Participant 
invitations also framed the screening offer within a broader 
’Lung Health Check’ including other lung tests (e.g., 
spirometry) rather than framing the offer solely as a cancer 
screening appointment, which aimed to minimise fear. 
There was also no upfront mention of smoking cessation 
which may disengage an important minority of current 
Figure 1 The behaviour change wheel. Note the central position of the necessary conditions for behaviour change of capability, opportunity, 
and motivation. 
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smokers (55). 
Much work has been done on improving engagement 
with people l iving in socioeconomically deprived 
communities, where a combination of practical measures 
that improve opportunity and tailored engagement also 
seem to be effective. These involve the invitation and 
reminder process as discussed above but also more practical 
issues such as the siting of the CT scanner and travel. The 
successful pilots in Manchester and Liverpool ensured easy 
access to scanners.
Future strategies to increase engagement in lung cancer 
screening may operate at multiple levels, ranging from lung 
screening awareness messages delivered at population level 
using targeted mass media and social media campaigns, 
to community health educators facilitating uptake in 
local target populations, to paper-based or digital tailored 
invitation materials designed to encourage engagement at 
an individual level. Such interventions must, however, be 
carefully developed and evaluated with principles of co-
production in mind. Where population data are limited, 
true for most countries without an established national 
primary care database, there may be difficulties identifying 
people who are at high risk and therefore potentially eligible 
for screening. Here, a method of identifying geographical 
regions with a higher incidence of lung cancer may allow 
effective targeting of engagement strategies. If this is 
combined with invitation methods that are effective in the 
social sector, participation rates may be improved. There 
are a number of sociodemographic “segmentations” that 
may allow this and this approach has been used to identify 
and target health interventions in COPD and congestive 
heart failure (56). 
The majority of benefit in cancer screening programmes 
is derived from continued involvement in the programme. 
This is because most cancers are found during the incidence 
screening rounds. It is therefore essential that participation 
in subsequent screening rounds in the programme is 
maximised. Similar approaches to those used in initial 
engagement therefore need to be employed to support 
continued participation and further research is needed to 
establish the key factors that improve adherence.
Conclusions
There is much work to do to ensure that LDCT screening 
programmes deliver their full potential to improve lung 
cancer outcomes. Improving informed participation is one 
of the most important elements in realising this potential. 
With the COVID-19 pandemic likely to exacerbate 
inequalities in lung cancer outcomes (57), it is imperative 
to commence planning for strategies to mitigate impact on 
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